Abstract
This article takes a broad perspective of community-acquired pneumonia (CAP). The arguments and data that support or refute the current approaches to initial antimicrobial treatment of CAP as outlined in the American Thoracic Society and Infectious Disease Society of America documents are provided. The complex issues involved in the decision of how to properly treat CAP are addressed.
MeSH terms
-
Anti-Bacterial Agents / therapeutic use*
-
Community-Acquired Infections / diagnosis
-
Community-Acquired Infections / drug therapy
-
Drug Resistance, Microbial
-
Female
-
Gram-Negative Bacteria / drug effects
-
Humans
-
Male
-
Pneumonia, Bacterial / diagnosis
-
Pneumonia, Bacterial / drug therapy*
-
Pneumonia, Bacterial / microbiology
-
Prognosis
-
Streptococcus pneumoniae / drug effects
-
Treatment Outcome